Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Viracta lays off 23% of staff, pauses program to slim down for race to finish line in lymphoma
Fierce Biotech
Wednesday, August 14, 2024 - 11:18am
tags:
Viracta Therapeutics, layoffs, solid tumors, valganciclovir, peripheral T-cell lymphoma
Evotec, citing research spending slowdown, cuts jobs and exits gene therapy
BioPharma Dive
Wednesday, August 14, 2024 - 11:09am
tags:
Evotec, CDMO, layoffs, restructuring
Pfizer appoints AI chief, expanding digital leadership team
BioPharma Dive
Wednesday, August 14, 2024 - 11:07am
tags:
Pfizer, artificial intelligence, digital pharma
Kezar stalls solid tumor trial to focus on autoimmune disease candidate
Pharmaceutical Technology
Wednesday, August 14, 2024 - 11:05am
tags:
Kezar Life Sciences, zetomipzomib, clinical trials, lupus, autoimmune hepatitis, solid tumors
Lexicon to lay off 50% of field force as it prioritizes heart failure drug, potential US diabetes launch
Fierce Pharma
Wednesday, August 14, 2024 - 11:03am
tags:
Lexicon Pharmaceuticals, type 1 diabetes, sotagliflozin, layoffs, restructuring
Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope.
Pharma Voice
Wednesday, August 14, 2024 - 11:02am
tags:
BioNTech, COVID-19, MRNA, oncology, cancer
What to watch when Medicare releases first negotiated drug prices
Axios
Wednesday, August 14, 2024 - 11:01am
tags:
Joe Biden, Medicare, drug pricing, Inflation Reduction Act
AI medtech specialist Firefly lists on Nasdaq after merger
Pharmaphorum
Wednesday, August 14, 2024 - 10:59am
tags:
Medtech, Firefly Neuroscience, NASDAQ, WaveDancer, artificial intelligence
AstraZeneca’s Imfinzi-Lynparza Combo Wins Landmark EU Nod for Endometrial Cancer
BioSpace
Wednesday, August 14, 2024 - 10:58am
tags:
AstraZeneca, Europe, Imfinzi, Lynparza, endometrial cancer
Abbott’s FreeStyle Libre CGM Meets Medtronic’s Insulin Delivery
Xtalks
Tuesday, August 13, 2024 - 11:11pm
tags:
Abbott Labs, Medtronic, Medtech, diabetes, CGMs, insulin
Investor activism resurfaces at Aurinia after CEO’s board role, exec pay lost majority support
Fierce Pharma
Tuesday, August 13, 2024 - 11:10pm
tags:
Aurinia, Robert Foster, activist investors
Amgen sues Samsung biotech unit over bone drug copies
Reuters
Tuesday, August 13, 2024 - 11:08pm
tags:
Amgen, Samsung, biologics, biosimilars, legal, Prolia, Xgeva
Acelyrin shifts from main drug, lays off staff
BioPharma Dive
Tuesday, August 13, 2024 - 11:03pm
tags:
Acelyrin, layoffs, izokibep, lonigutamab, thyroid eye disease
Illumina, CRISPR-pioneer Broad Institute to work on new gene sequencing kits
Reuters
Tuesday, August 13, 2024 - 11:01pm
tags:
Illumina, Medtech, Broad Institute, CRISPR, gene sequencing
The ‘Sledgehammer’ Approach to Recycling Medical Plastics
Medical Devices and Diagnostics Industry
Tuesday, August 13, 2024 - 10:59pm
tags:
recycling, Medtech, plastics, sustainability
Eli Lilly unwraps $700M nucleic acid R&D center in Boston Seaport, opens doors to biotechs
Fierce Biotech
Tuesday, August 13, 2024 - 11:49am
tags:
Eli Lilly, Boston, R&D, DNA, RNA
5 Obesity Readouts to Watch in the Second Half of 2024
BioSpace
Tuesday, August 13, 2024 - 11:47am
tags:
obesity, clinical trials, Novo Nordisk, CagriSema, Amgen, MariTide, Monlunabant, Aphaia Pharma, APHD-012, Terns Pharmaceuticals, TERN-601
Can Rite Aid Recover?
Drug Channels
Tuesday, August 13, 2024 - 11:41am
tags:
Rite Aid, pharmacies, bankruptcy
Enzo Biochem to pay $4.5 mln over cyberattack, NY attorney general says
Reuters
Tuesday, August 13, 2024 - 11:40am
tags:
Enzo Biochem, New York, cyberattack, cybersecurity
J&J has enough support for $6.5 bln talc settlement
Yahoo/Reuters
Tuesday, August 13, 2024 - 11:38am
tags:
JNJ, legal, bankruptcy

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.